152.72
前日終値:
$155.07
開ける:
$154.05
24時間の取引高:
672.33K
Relative Volume:
0.69
時価総額:
$8.97B
収益:
$551.35M
当期純損益:
$-189.33M
株価収益率:
-46.40
EPS:
-3.2916
ネットキャッシュフロー:
$-35.09M
1週間 パフォーマンス:
+2.95%
1か月 パフォーマンス:
+24.68%
6か月 パフォーマンス:
+35.25%
1年 パフォーマンス:
+43.33%
Glaukos Corp Stock (GKOS) Company Profile
Compare GKOS vs ABT, SYK, MDT, BSX, EW
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
GKOS
Glaukos Corp
|
152.72 | 8.97B | 551.35M | -189.33M | -35.09M | -3.2916 |
|
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
|
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
|
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
|
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
|
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Glaukos Corp Stock (GKOS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-27 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-10-01 | 開始されました | Goldman | Buy |
| 2025-05-01 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-02-19 | アップグレード | Mizuho | Neutral → Outperform |
| 2024-12-11 | アップグレード | Citigroup | Neutral → Buy |
| 2024-12-06 | 開始されました | UBS | Buy |
| 2024-12-02 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2024-07-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-05-06 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-21 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-12-04 | 開始されました | Morgan Stanley | Equal-Weight |
| 2023-11-28 | 開始されました | Truist | Buy |
| 2023-11-08 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-07 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-12-22 | 開始されました | Mizuho | Neutral |
| 2022-12-19 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-12-12 | アップグレード | Citigroup | Neutral → Buy |
| 2022-10-14 | 再開されました | Stephens | Overweight |
| 2022-10-04 | 開始されました | Needham | Buy |
| 2022-07-12 | アップグレード | Stifel | Hold → Buy |
| 2022-02-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2022-01-19 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-01-18 | アップグレード | BTIG Research | Neutral → Buy |
| 2021-11-03 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2021-07-26 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2021-07-20 | ダウングレード | Wells Fargo | Equal Weight → Underweight |
| 2021-07-14 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-07-14 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2021-04-08 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-01-29 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2020-12-16 | アップグレード | Citigroup | Sell → Neutral |
| 2020-12-09 | 開始されました | Oppenheimer | Perform |
| 2020-11-17 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2020-10-08 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-06-15 | 開始されました | Jefferies | Hold |
| 2020-03-05 | 開始されました | Citigroup | Sell |
| 2020-02-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-01-06 | アップグレード | Berenberg | Hold → Buy |
| 2019-12-12 | ダウングレード | Wells Fargo | Outperform → Underperform |
| 2019-09-30 | ダウングレード | BofA/Merrill | Buy → Underperform |
| 2019-03-08 | 開始されました | BTIG Research | Neutral |
| 2018-08-30 | 開始されました | Berenberg | Hold |
| 2018-08-29 | アップグレード | JP Morgan | Neutral → Overweight |
| 2018-08-03 | 繰り返されました | Stifel | Hold |
| 2018-06-21 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-04-13 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-01 | 繰り返されました | Cantor Fitzgerald | Buy |
| 2017-03-02 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2017-01-06 | アップグレード | Stifel | Hold → Buy |
| 2016-10-27 | 開始されました | Wells Fargo | Outperform |
すべてを表示
Glaukos Corp (GKOS) 最新ニュース
Price to sales forward of Glaukos Corp – XETR:6GJ - TradingView
Form 144 GLAUKOS Corp For: 9 July By Investing.com - Investing.com South Africa
Form 144 GLAUKOS Corp For: 9 July - Investing.com UK
Midday Stock Roundup: Alignment Healthcare Up 7.8% Ahead of Q2 Results - Orange County Business Journal
Glaukos (GKOS) Form 144 shows 10,000-share sale, option exercise - Stock Titan
Glaukos Corp CFO Alex Thurman sells $1.5m in shares - Investing.com
Form 4 Glaukos Corp For: 8 July By Investing.com - Investing.com Nigeria
Glaukos chief development officer Navratil sells $99,566 stock By Investing.com - Investing.com Nigeria
Glaukos (GKOS) CFO executes pre-planned share sale and option exercise - Stock Titan
Glaukos chief development officer Navratil sells $99,566 stock - Investing.com
Glaukos (GKOS) chief development officer sells 716 shares under 10b5-1 plan - Stock Titan
Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
GKOS Maintained by Citigroup -- Price Target Raised to $175 - GuruFocus
GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally? - Yahoo Finance
Glaukos to Release Second Quarter 2026 Financial Results after Market Close on July 29 - Business Wire
Glaukos Corp stock and its role in eye disease treatment - ad-hoc-news.de
Form 144 GLAUKOS Corp For: 6 July By Investing.com - Investing.com Nigeria
Glaukos (NYSE: GKOS) files Form 144 to sell 10,000 shares - Stock Titan
Glaukos stock rating reiterated at Outperform by William Blair - Investing.com
Glaukos Rises as Reimbursement Milestone and Recent Pipeline Updates Support Sentiment - Quiver Quantitative
Glaukos stock hits 52-week high at 148.12 USD By Investing.com - Investing.com Nigeria
Glaukos stock hits 52-week high at 148.12 USD - Investing.com
Form 144 GLAUKOS Corp For: 1 July - Investing.com UK
Form 144 GLAUKOS Corp For: 1 July By Investing.com - Investing.com Canada
GKOS (GKOS) insider sells 3,630 shares total across April and June 2026 - Stock Titan
GKOS Reiterated by Piper Sandler -- Price Target Maintained at $165 - GuruFocus
Piper Sandler reiterates Glaukos stock rating on iDose headwinds By Investing.com - Investing.com Nigeria
Piper Sandler reiterates Glaukos stock rating on iDose headwinds - Investing.com
Form 4 Glaukos Corp For: 29 June By Investing.com - Investing.com South Africa
Glaukos (NYSE: GKOS) CEO updates trust holdings, uses shares for tax withholding - Stock Titan
Form 4 Glaukos Corp For: 29 June - Investing.com UK
Glaukos (NYSE: GKOS) president has 1,056 shares withheld for taxes - Stock Titan
Glaukos (GKOS) CDO reports 483-share tax withholding, holds 88,350 shares - Stock Titan
Enterprise value to EBIT forward of Glaukos Corp – XETR:6GJ - TradingView
Price to book forward of Glaukos Corp – XETR:6GJ - TradingView
Enterprise value to EBITDA forward of Glaukos Corp – XETR:6GJ - TradingView
Goldman Sachs Small Cap Equity Insights Fund's Glaukos Corp(GKOS) Holding History - GuruFocus
Glaukos Corp Actuals & Estimates (NYSE:GKOS) - TradingView
Glaukos Moves Into Demodex Blepharitis Space - Orange County Business Journal
Glaukos completes enrollment in phase 2 blepharitis study - Investing.com
Glaukos Announces Completion of Patient Enrollment in Phase 2 Study of GLK-321 for Demodex Blepharitis - BioSpace
Glaukos completes enrollment in phase 2 blepharitis study By Investing.com - Investing.com Australia
Glaukos (GKOS) Completes Patient Enrollment in GLK-321 Study - GuruFocus
Glaukos fills 275-patient trial of eyelid-disease drug candidate - Stock Titan
Glaukos Corp (GKOS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Form 4 Glaukos Corp For: 23 June By Investing.com - Investing.com Nigeria
Form 4 Glaukos Corp For: 23 June - Investing.com UK
Glaukos (NYSE: GKOS) director updates stock option grant to $106.52 strike - Stock Titan
Glaukos (NYSE: GKOS) director Leana Wen awarded 2,987 stock options at $106.52 - Stock Titan
GLAUKOS (GKOS) director Stapley gets 2,987 options at corrected $106.52 strike - Stock Titan
Glaukos Corp (GKOS) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):